Literature DB >> 20336693

Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts.

Damian C Genetos1, Chrisoula A Toupadakis, Leah F Raheja, Alice Wong, Savvas E Papanicolaou, David P Fyhrie, Gabriela G Loots, Clare E Yellowley.   

Abstract

Mutations in sclerostin function or expression cause sclerosing bone dysplasias, involving decreased antagonism of Wnt/Lrp5 signaling. Conversely, deletion of the VHL tumor suppressor in osteoblasts, which stabilize HIF-alpha isoforms and thereby enables HIF-alpha/beta-driven gene transcription, increases bone mineral content and cross-sectional area compared to wild-type controls. We examined the influence of cellular hypoxia (1% oxygen) upon sclerostin expression and canonical Wnt signaling. Osteoblasts and osteocytes cultured under hypoxia revealed decreased sclerostin transcript and protein, and increased expression and nuclear localization of activated beta-catenin. Similarly, both hypoxia and the hypoxia mimetic DFO increased beta-catenin gene reporter activity. Hypoxia and its mimetics increased expression of the BMP antagonists gremlin and noggin and decreased Smad-1/5/8 phosphorylation. As a partial explanation for the mechanism of regulation of sclerostin by oxygen, MEF2 reporter assays revealed decreased activity. Modulation of VEGF signaling under normoxia or hypoxia revealed no influence upon Sost transcription. These data suggest that hypoxia inhibits sclerostin expression, through enhanced antagonism of BMP signaling independent of VEGF. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336693      PMCID: PMC2881162          DOI: 10.1002/jcb.22559

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  44 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

3.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

4.  Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.

Authors:  Naoki Kusu; Johanna Laurikkala; Mayumi Imanishi; Hiroko Usui; Morichika Konishi; Ayumi Miyake; Irma Thesleff; Nobuyuki Itoh
Journal:  J Biol Chem       Date:  2003-04-17       Impact factor: 5.157

5.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

6.  [Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].

Authors:  I González Suárez; J L Fernández Martín; M Naves Díaz; J B Cannata Andía
Journal:  Nefrologia       Date:  2003       Impact factor: 2.033

7.  Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.

Authors:  Jon E Wergedal; Katarina Veskovic; Minea Hellan; Christine Nyght; Wendy Balemans; Cesar Libanati; Filip M Vanhoenacker; Johan Tan; David J Baylink; Wim Van Hul
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

8.  High bone mass in mice expressing a mutant LRP5 gene.

Authors:  Philip Babij; Weiguang Zhao; Clayton Small; Yogendra Kharode; Paul J Yaworsky; Mary L Bouxsein; Padmalatha S Reddy; Peter V N Bodine; John A Robinson; Bheem Bhat; James Marzolf; Robert A Moran; Frederick Bex
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

9.  Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells.

Authors:  J H Park; B H Park; H K Kim; T S Park; H S Baek
Journal:  Mol Cell Endocrinol       Date:  2002-06-28       Impact factor: 4.102

10.  Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.

Authors:  Nobuhiro Kamiya; Tatsuya Kobayashi; Yoshiyuki Mochida; Paul B Yu; Mitsuo Yamauchi; Henry M Kronenberg; Yuji Mishina
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

View more
  56 in total

1.  Long-term administration of AMD3100, an antagonist of SDF-1/CXCR4 signaling, alters fracture repair.

Authors:  Chrisoula A Toupadakis; Alice Wong; Damian C Genetos; Dai-Jung Chung; Deepa Murugesh; Matthew J Anderson; Gabriela G Loots; Blaine A Christiansen; Amy S Kapatkin; Clare E Yellowley
Journal:  J Orthop Res       Date:  2012-05-16       Impact factor: 3.494

2.  Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients.

Authors:  P D'Amelio; F Sassi; I Buondonno; G Fornelli; E Spertino; L D'Amico; M Marchetti; M Lucchiari; I Roato; G C Isaia
Journal:  Osteoporos Int       Date:  2015-06-12       Impact factor: 4.507

Review 3.  Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies.

Authors:  Betsabel Chicana; Cristine Donham; Alberto J Millan; Jennifer O Manilay
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

Review 4.  Obstructive sleep apnea and metabolic bone disease: insights into the relationship between bone and sleep.

Authors:  Christine M Swanson; Steven A Shea; Katie L Stone; Jane A Cauley; Clifford J Rosen; Susan Redline; Gerard Karsenty; Eric S Orwoll
Journal:  J Bone Miner Res       Date:  2015-02       Impact factor: 6.741

Review 5.  A review of osteocyte function and the emerging importance of sclerostin.

Authors:  Jocelyn T Compton; Francis Y Lee
Journal:  J Bone Joint Surg Am       Date:  2014-10-01       Impact factor: 5.284

Review 6.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

7.  Specification of Sprouty2 functions in osteogenesis in in vivo context.

Authors:  Barbora Vesela; Eva Svandova; Maria Hovorakova; Renata Peterkova; Adela Kratochvilova; Martina Pasovska; Alice Ramesova; Herve Lesot; Eva Matalova
Journal:  Organogenesis       Date:  2019-09-04       Impact factor: 2.500

8.  The expression of Wnt-inhibitor DKK1 (Dickkopf 1) is determined by intercellular crosstalk and hypoxia in human malignant gliomas.

Authors:  Ke-Tai Guo; Peng Fu; Kathrin Juerchott; Helena Motaln; Joachim Selbig; Tamara Lah; Jörg-Christian Tonn; Christian Schichor
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-27       Impact factor: 4.553

9.  Estrogen-mimicking isoflavone genistein prevents bone loss in a rat model of obstructive sleep apnea-hypopnea syndrome.

Authors:  Lige Song; Xiao Liang; Yun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  The role of oxygen during fracture healing.

Authors:  Chuanyong Lu; Neema Saless; Xiaodong Wang; Arjun Sinha; Sebastian Decker; Galateia Kazakia; Huagang Hou; Benjamin Williams; Harold M Swartz; Thomas K Hunt; Theodore Miclau; Ralph S Marcucio
Journal:  Bone       Date:  2012-10-12       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.